Table 2.
Factors affecting adherence to intensive phase of MDR-TB treatment
| Adherence to policy during intensive phase | |||
| Good adherence/ n (%) | Poor adherence/ n (%) | p.value | |
|---|---|---|---|
| Facility DOT supervision | |||
| Peripheral- | |||
| DOTs | 71 (26.50) | 197 (73.50) | |
| Central-DOTs | 0 (0.00) | 51 (100.00) | <0.001* |
| RECODE of AGE | |||
| (AGE) | |||
| 15–25 | 31 (30.40) | 71 (69.60) | |
| 26–35 | 18 (16.40) | 92 (83.60) | |
| >=36 | 22 (20.60) | 85 (79.40) | 0.043* |
| SEX | |||
| Female | 28 (23.10) | 93 (76.90) | |
| Male | 43 (21.70) | 155 (78.30) | 0.767 |
| TYPE OF | |||
| PATIENT | |||
| New | 39 (24.10) | 123 (75.90) | |
| Retreatment | 32 (20.40) | 125 (79.60) | 0.428 |
| CONTACTS SCREENED? | |||
| No | 1 (3.60) | 27 (96.40) | |
| Yes | 70 (24.10) | 221 (75.90) | 0.013* |
| REGIMEN TYPE | |||
| Empirical | 2 (28.60) | 5 (71.40) | |
| Standard | 67 (23.30) | 220 (76.70) | |
| Individualized | 2 (8.70) | 21 (91.30) | 0.248 |
| HIV STATUS | |||
| Positive | 34 (19.80) | 138 (80.20) | |
| Negative | 37 (25.30) | 109 (74.70) | 0.234 |
*
Variable is significant using a p-value of . 0.05 for statistical significance